Replies to post #33 on Boston Scientific Corp (BSX)

[mlkrborn]

Boston Scientific receives FDA approval for PROMUS Element plus platinum chromium stent system (BSX) 5.31 : The co expects to record a pre-tax charge of ~$40 mln ($35 mln after-tax) during the fourth quarter of 2011 as a result of the early approval and launch timing of the PROMUS Element Plus Stent System in the U.S. primarily related to inventory reserves which will impact gross margins. This charge was not included in the co's previously issued financial guidance for the fourth quarter.